Oestrogen is the primary regulator of bone remodelling in women. It suppresses osteoclast activity, the cells that break down bone, and supports osteoblast activity, the cells that build it. When oestrogen declines at the menopause, osteoclast activity accelerates and is no longer balanced by equivalent bone formation. The result is the fastest period of bone loss in adult life: on average, women lose two to three percent of spinal bone density per year in the two to three years immediately following the final menstrual period, and one to two percent per year for several years after that. The cumulative loss over the perimenopausal and early postmenopausal decade averages 10 to 20 percent of total bone mass.
Why This Matters for Lifetime Fracture Risk
One in two women over 50 will sustain an osteoporosis-related fracture in their lifetime. Hip fracture is associated with a one-year mortality rate of 20 to 30 percent in older adults, making it a significant predictor of premature death. Vertebral fractures, often occurring without major trauma, cause chronic pain, height loss, and kyphosis. The bone density at which a woman exits the menopausal transition is the primary modifiable determinant of her fracture risk in later decades. What is built or maintained now sets the trajectory for the following 30 to 40 years.
Hormone Replacement Therapy and Bone
HRT containing oestrogen is the most effective available intervention for preventing menopausal bone loss. The Women's Health Initiative trial demonstrated significant reductions in hip, vertebral, and total fracture rates with combined oestrogen-progestogen therapy. The NICE menopause guideline explicitly recommends HRT for the prevention of osteoporosis in menopausal women below age 60 in the absence of contraindications. For women who start HRT within 10 years of the menopause, the benefits substantially outweigh the risks in the majority of cases.
Non-Pharmacological Bone Preservation
Impact-loading exercise, particularly resistance training and activities involving jumping or rapid changes of direction, is the most effective exercise intervention for preserving bone density in menopausal women. A Cochrane review found that progressive resistance training produced significant improvements in spinal and hip bone density in postmenopausal women. Calcium intake of 1000 to 1200mg per day from food, combined with adequate vitamin D to ensure absorption, is the nutritional foundation. Protein adequacy is also important: the matrix of bone is primarily collagen, and adequate protein intake supports bone matrix quality independent of mineral density.
- Undertake progressive resistance training at least twice weekly: this is the most evidence-based non-hormonal bone preservation strategy
- Discuss HRT with your GP or gynaecologist if you are within 10 years of your final period: bone protection is a primary indication
- Ensure calcium intake of 1000 to 1200mg daily from food sources: dairy, fortified plant milks, sardines with bones, and firm tofu
- Supplement vitamin D3 year-round if you are postmenopausal: adequate vitamin D is essential for calcium absorption
- Request a DEXA bone density scan at menopause to establish your baseline and guide subsequent monitoring
Sources
- NICE. (2015, updated 2019). Menopause: diagnosis and management. NICE guideline NG23.
- Cauley, J.A. (2015). Estrogen and bone health in men and women. Steroids, 99, 11-15.
- Marjoribanks, J., et al. (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, 1, CD004143.